Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.79 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.55 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.55 |
| ▸ | STS | P08842 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CCR4 | P51679 | 1/20 | 0.38 |
| ▸ | EDNRB | P24530 | 1/20 | 0.38 |
| ▸ | EDNRA | P25101 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6625837 | 0.91 | HSD11B1 (0.67) | HSD11B1HSD17B1HSD17B2STSLMNA | |
| SCHEMBL3254706 | 0.89 | HSD11B1 (0.86) | HSD11B1HSD17B1HSD17B2TP53CCR4 | |
| SCHEMBL3250977 | 0.89 | HSD11B1 (0.86) | HSD11B1HSD17B1HSD17B2CCR4EDNRB | |
| SCHEMBL3255788 | 0.88 | HSD11B1 (0.84) | HSD11B1HSD17B1HSD17B2CCR4EDNRB | |
| SCHEMBL3255959 | 0.87 | HSD11B1 (0.83) | HSD11B1HSD17B1HSD17B2LMNAPOLB | |
| SCHEMBL3253535 | 0.87 | HSD11B1 (0.83) | HSD11B1HSD17B1HSD17B2CCR4EDNRB | |
| SCHEMBL3256129 | 0.86 | HSD11B1 (0.82) | HSD11B1HSD17B1HSD17B2CCR4EDNRB | |
| SCHEMBL5830654 | 0.85 | HSD11B1 (0.58) | HSD11B1HSD17B1HSD17B2STSLMNA | |
| SCHEMBL5831277 | 0.84 | HSD11B1 (0.58) | HSD11B1HSD17B1HSD17B2STSLMNA | |
| SCHEMBL3605403 | 0.83 | HSD11B1 (0.79) | HSD11B1HSD17B1HSD17B2STSLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1461325-B1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2010-05-26 | — | — | EP | claimed |
| US-7671051-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2010-03-02 | — | — | US | claimed |
| US-20050250776-A1 | Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 | BIOVITRUM AB | 2005-11-10 | — | — | US | claimed |
| US-20030130318-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | claimed |
| WO-2019075394-A1 | COMPOUNDS FOR TREATMENT OF EMOTIONAL/PSYCHOLOGICAL SYMPTOMS IN FRAGILE X SYNDROME | VANDERKLISH PETER (US) | 2019-04-18 | — | — | WO | disclosed |
| EP-1461325-B1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2010-05-26 | — | — | EP | disclosed |
| US-7671051-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2010-03-02 | — | — | US | disclosed |
| US-7094792-B2 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2006-08-22 | — | — | US | disclosed |
| US-20050250776-A1 | Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 | BIOVITRUM AB | 2005-11-10 | — | — | US | disclosed |
| US-20030130318-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250776-A1 | Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 | HSD11B1, HSD17B1, HSD17B11 | HSD11B1 1/4885HSD17B1 2/4885HSD17B2 6/4885 |
| US-20030130318-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885HSD17B1 2/4885HSD17B2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.